Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company listed on the Nasdaq Composite Russell 1000 ...

Fintel reports that on June 18, 2025, LifeSci Capital initiated coverage of GlycoMimetics (NasdaqCM:CBIO) with a Outperform ...

Fintel reports that on June 18, 2025, LifeSci Capital downgraded their outlook for Verve Therapeutics (NasdaqGS:VERV) from ...

Detailed price information for Beam Therapeutics Inc (BEAM-Q) from The Globe and Mail including charting and trades.

But we knew this access policy was too good to last, and now we have an end date: Feb 1, 2026. Venture X and Capital One Venture X Business cardholders received an email notifying them of sweeping ...

Detailed price information for Perspective Therapeutics Inc (CATX-A) from The Globe and Mail including charting and trades.

The Fund seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index. The Index seeks to track the ...

Joshua Kushner’s Thrive Capital and investment firm Capital Group have in recent months visited China to learn about its AI industry, joining a growing number of US investors rekindling interest ...

In an email to Venture X and Venture X Business cardholders this week and confirmed on the Capital One website, the card issuer announced that its airport lounge access rules – among the most ...

MiddleGround Capital is working with an investment bank to launch a sale process for its portfolio company Vytl Controls Group in the coming weeks, three sources briefed on the matter told PE Hub.